Landmark science has led to an inundation of new transformative therapies, but is the cell and gene market at the point of saturation?

What techniques can pharma companies adopt and adapt from the tech giants dominating the stage of modern-day innovation?

What drives Novartis Oncology’s Reshema Kemps-Polanco to succeed?

Five minutes with Anat Cohen-Dayag, CEO of clinical-stage drug discovery and development company Compugen.

After dizzying heights of investment during the pandemic, biotechs have observed a slump, but the future may look more promising.

AI is being implemented into drug development to free up time, money and manpower, but how can humans and computers work together?

In his first regular column for GOLD, Davidek Herron discusses digital transformation in pharma and pursuing operational excellence.

With opioid abuse showing little sign of abating, what role can pharma play in addressing the crisis?